Synergistic effects of ATAD2 inhibitor with tamoxifen on ER-positive breast cancer cells
Royer, Cole
Royer, Cole
Citations
Altmetric:
License
0
License
DOI
Abstract
ATAD2 is a chromatin-associated protein with roles in DNA replication and transcription. ATAD2 is associated with poor breast cancer outcomes and is a possible therapeutic target in cancer, exploring drugs that inhibit ATAD2 function is important. ATAD2 has a bromodomain that recognizes acetylated lysine residues in histone proteins. Inhibitors that target bromodomains hold promise as anticancer drugs. Preliminary data revealed a decrease in cellular viability of breast cancer cells using ATAD2 inhibitor (BAY850). Ongoing and future studies aim to explore mechanism(s) of BAY850 by evaluating its effect on cells to outline its mechanisms of action in ER+ breast cancer cells.
Description
Undergraduate
Date
2023-01-01